ERBB2 and breast carcinoma: In addition, ABRAZO patients exhibited a relatively high observed fraction of gLOH-high tumors (≥16% gLOH score20), which was also similar to that reported in HER2– gBRCA1/2mut breast cancer (78.1%; 82.3% for gBRCA1mut and 74.9% for gBRCA2mut) and over two-fold higher than that observed in the overall breast cancer population (35.3%) in the Foundation Medicine database.